Some papers have suggested [58, 60] that prostaglandin and PPARγ activated by its metabolic derivatives inhibit the growth and proliferation of pancreatic cancer cells in a certain dose-dependent manner; rosiglitazone and metformin, either used alone or combined, both inhibit the growth and proliferation of pancreatic cancer in vitro and promote the tumor cell apoptosis, and it has been found that the potency of their combination is stronger than that of either single drug. Here, PPARG is linked to neoplasm.